Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TQA3605 in Treatment-naive HBeAg-positive Chronic HBV
NCT06990776Phase 2Withdrawn
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQA3605 in Chronic Hepatitis B (CHB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jul 2025; status: withdrawn.
02
Drugs
TQA3605
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06990776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990776.